195 related articles for article (PubMed ID: 29889862)
41. Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa.
Boender TS; Hoenderboom BM; Sigaloff KC; Hamers RL; Wellington M; Shamu T; Siwale M; Labib Maksimos EE; Nankya I; Kityo CM; Adeyemo TA; Akanmu AS; Mandaliya K; Botes ME; Ondoa P; Rinke de Wit TF
Clin Infect Dis; 2015 Dec; 61(11):1749-58. PubMed ID: 26240203
[TBL] [Abstract][Full Text] [Related]
42. Longitudinal Viral Suppression Among a Cohort of Adolescents and Young Adults with Behaviorally Acquired Human Immunodeficiency Virus.
Wood SM; Lowenthal E; Lee S; Ratcliffe SJ; Dowshen N
AIDS Patient Care STDS; 2017 Sep; 31(9):377-383. PubMed ID: 28891717
[TBL] [Abstract][Full Text] [Related]
43. Viral load monitoring for people living with HIV in the era of test and treat: progress made and challenges ahead - a systematic review.
Pham MD; Nguyen HV; Anderson D; Crowe S; Luchters S
BMC Public Health; 2022 Jun; 22(1):1203. PubMed ID: 35710413
[TBL] [Abstract][Full Text] [Related]
44. Frequency of Viremic Episodes in HIV-Infected Women Initiating Antiretroviral Therapy During Pregnancy: A Cohort Study.
Myer L; Dunning L; Lesosky M; Hsiao NY; Phillips T; Petro G; Zerbe A; McIntyre JA; Abrams EJ
Clin Infect Dis; 2017 Feb; 64(4):422-427. PubMed ID: 27927852
[TBL] [Abstract][Full Text] [Related]
45. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.
Haas AD; Keiser O; Balestre E; Brown S; Bissagnene E; Chimbetete C; Dabis F; Davies MA; Hoffmann CJ; Oyaro P; Parkes-Ratanshi R; Reynolds SJ; Sikazwe I; Wools-Kaloustian K; Zannou DM; Wandeler G; Egger M;
Lancet HIV; 2015 Jul; 2(7):e271-8. PubMed ID: 26423252
[TBL] [Abstract][Full Text] [Related]
46. Risk factors associated with unsuppressed viral load in HIV-1 infected patients at the first antiretroviral therapy in Morocco.
Hicham T; Ilyas E; Tarik H; Noureddine B; Omar B; Rachid F; Naoufal H; Mohammed B
Int J Mycobacteriol; 2019; 8(2):113-117. PubMed ID: 31210151
[TBL] [Abstract][Full Text] [Related]
47. Patterns of adherence to antiretroviral therapy and HIV drug resistance over time in the Stratall ANRS 12110/ESTHER trial in Cameroon.
Meresse M; March L; Kouanfack C; Bonono RC; Boyer S; Laborde-Balen G; Aghokeng A; Suzan-Monti M; Delaporte E; Spire B; Carrieri MP; Laurent C;
HIV Med; 2014 Sep; 15(8):478-87. PubMed ID: 24589279
[TBL] [Abstract][Full Text] [Related]
48. Trends in Prevalence of HIV-1 Drug Resistance in a Public Clinic in Maputo, Mozambique.
Bila DC; Boullosa LT; Vubil AS; Mabunda NJ; Abreu CM; Ismael N; Jani IV; Tanuri A
PLoS One; 2015; 10(7):e0130580. PubMed ID: 26151752
[TBL] [Abstract][Full Text] [Related]
49. Implementation and Operational Research: Correlates of Adherence and Treatment Failure Among Kenyan Patients on Long-term Highly Active Antiretroviral Therapy.
Ochieng W; Kitawi RC; Nzomo TJ; Mwatelah RS; Kimulwo MJ; Ochieng DJ; Kinyua J; Lagat N; Onyango KO; Lwembe RM; Mwamburi M; Ogutu BR; Oloo FA; Aman R
J Acquir Immune Defic Syndr; 2015 Jun; 69(2):e49-56. PubMed ID: 26009836
[TBL] [Abstract][Full Text] [Related]
50. Outcomes of protease inhibitor-based antiretroviral therapy amongst children and associated-factors in Yaoundé, Cameroon.
Njom Nlend AE; Guessong CO; Nga Motaze AC; Soffo C; Koki Ndombo PO; Tsambang L; Fokam J
PLoS One; 2019; 14(3):e0213900. PubMed ID: 30883591
[TBL] [Abstract][Full Text] [Related]
51. Implementation and operational feasibility of SAMBA I HIV-1 semi-quantitative viral load testing at the point-of-care in rural settings in Malawi and Uganda.
Gueguen M; Nicholas S; Poulet E; Schramm B; Szumilin E; Wolters L; Wapling J; Ajule E; Rakesh A; Mwenda R; Kiyaga C; Balkan S
Trop Med Int Health; 2021 Feb; 26(2):184-194. PubMed ID: 33159822
[TBL] [Abstract][Full Text] [Related]
52. Brief Report: Time to Repeat Viral Load Testing Among Unsuppressed Adolescents and Young Adults Living With HIV in Kenya.
Mugo C; Wilson KS; Onyango A; Njuguna IN; Mburu CW; Richardson BA; Oyiengo L; Inwani I; John-Stewart G; Wamalwa DC; Kohler PK
J Acquir Immune Defic Syndr; 2020 Dec; 85(5):606-611. PubMed ID: 32897936
[TBL] [Abstract][Full Text] [Related]
53. Increasing multimonth dispensing of antiretrovirals and assessing the effect on viral load suppression among children and adolescents receiving HIV services in Nigeria.
Casalini C; Bateganya M; Akolo C; Sanwo O; Idemudia A; Nwaokoro P; Eyam F; Ogbechie MD; Obiora-Okafo C; Oduola A; Wilcher R; Mack N; Khamofu H; Pandey SR
PLoS One; 2023; 18(6):e0286303. PubMed ID: 37315075
[TBL] [Abstract][Full Text] [Related]
54. Timeliness of Point-of-Care Viral Load Results Improves Human Immunodeficiency Virus Monitoring in Nigeria.
Chaplin B; Agbaji O; Reyes Nieva H; Olatunde B; Chang C; Mitruka K; Sule H; Dajel T; Zee A; Ahmed ML; Ahmed I; Okonkwo P; Rawizza H; Kanki P
Clin Infect Dis; 2023 Feb; 76(3):e671-e680. PubMed ID: 35872644
[TBL] [Abstract][Full Text] [Related]
55. Early HIV viral load determination after initiating first-line antiretroviral therapy for indentifying patients with high risk of developing virological failure: data from a cohort study in a resource-limited setting.
Alvarez-Uria G; Naik PK; Pakam R; Midde M
Trop Med Int Health; 2012 Sep; 17(9):1152-5. PubMed ID: 22487689
[TBL] [Abstract][Full Text] [Related]
56. Misdiagnosis of HIV treatment failure based on clinical and immunological criteria in Eastern and Central Kenya.
Joram SL; Paul G; Moses K; Stanley B; Isaac M; Allan G; Tom M; Lilian K; Mildred M
BMC Infect Dis; 2017 Jun; 17(1):383. PubMed ID: 28577527
[TBL] [Abstract][Full Text] [Related]
57. HIV Viral Load Monitoring Frequency and Risk of Treatment Failure among Immunologically Stable HIV-Infected Patients Prescribed Combination Antiretroviral Therapy.
Young B; Hart RL; Buchacz K; Scott M; Palella F; Brooks JT;
J Int Assoc Provid AIDS Care; 2015; 14(6):536-43. PubMed ID: 26293905
[TBL] [Abstract][Full Text] [Related]
58. Near Point-of-Care HIV Viral Load: Targeted Testing at Large Facilities.
Ganesh P; Heller T; Chione B; Gumulira J; Gugsa S; Khan S; McGovern S; Nhlema A; Nkhoma L; Sacks JA; Trapence C; Tweya H; Ehrenkranz P; Phiri S
J Acquir Immune Defic Syndr; 2021 Feb; 86(2):258-263. PubMed ID: 33136821
[TBL] [Abstract][Full Text] [Related]
59. Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa.
Boender TS; Hamers RL; Ondoa P; Wellington M; Chimbetete C; Siwale M; Labib Maksimos EE; Balinda SN; Kityo CM; Adeyemo TA; Akanmu AS; Mandaliya K; Botes ME; Stevens W; Rinke de Wit TF; Sigaloff KC
J Infect Dis; 2016 Sep; 214(6):873-83. PubMed ID: 27402780
[TBL] [Abstract][Full Text] [Related]
60. High efficacy of first-line ART in a West African cohort, assessed by dried blood spot virological and pharmacological measurements.
de Truchis P; Lê MP; Daou M; Madougou B; Nouhou Y; Moussa Saley S; Sani A; Adehossi E; Rouveix E; Saidou M; Peytavin G; Delaugerre C
J Antimicrob Chemother; 2016 Nov; 71(11):3222-3227. PubMed ID: 27439522
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
